Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-10-07 07:10 |
Biophytis to Restate Previously Issued Financial Statements
|
English | 168.1 KB | ||
| 2021-10-07 07:10 |
Biophytis va retraiter les états financiers publiés antérieurement
|
French | 161.2 KB | ||
| 2021-10-06 08:00 |
Biophytis to host virtual KOL event on Sarconeos (BIO101) on its lead projects …
|
English | 164.4 KB | ||
| 2021-10-06 08:00 |
Biophytis organise un évènement avec les KOLs sur Sarconeos (BIO101) dans le tr…
|
French | 168.6 KB | ||
| 2021-10-04 23:00 |
Biophytis announces the drawing of 2 new tranches of ORNANE under the 2020 Atla…
|
English | 153.1 KB | ||
| 2021-10-04 23:00 |
Biophyis annonce le tirage de deux nouvelles tranches d'ORNANE dans le cadre du…
|
French | 184.1 KB | ||
| 2021-09-29 08:00 |
Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos…
|
English | 162.7 KB | ||
| 2021-09-29 08:00 |
Biophytis présentera les résultats complets de L’étude de phase 2-b, SARA-INT, …
|
French | 178.5 KB | ||
| 2021-09-17 08:00 |
Biophytis reports H1 2021 financial results and provides business update
|
English | 262.7 KB | ||
| 2021-09-17 08:00 |
Biophytis publie ses résultats financiers du 1er semestre 2021 et fait le point…
|
French | 209.2 KB | ||
| 2021-09-15 08:00 |
Biophytis announces DMC second interim analysis efficacy results in the promisi…
|
English | 232.0 KB | ||
| 2021-09-15 08:00 |
Biophytis annonce les résultats de la deuxième analyse intermédiaire du DMC dan…
|
French | 489.1 KB | ||
| 2021-09-14 08:00 |
Biophytis to attend key upcoming investor events and industry conferences
|
English | 179.8 KB | ||
| 2021-09-14 08:00 |
Biophytis participera à plusieurs événements investisseurs et conférences clés …
|
French | 171.5 KB | ||
| 2021-09-09 08:00 |
Biophytis leadership is reinforced with new Chief Medical Officer appointment
|
English | 165.5 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
